REPROCELL Europe, a provider of products and services for research in stem cells, drug discovery, human tissues, 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
The new headquarters will strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland.
The REPROCELL Centre for Predictive Drug Discovery at West of Scotland Science Park was inaugurated by Scotland’s First Minister, Nicola Sturgeon.
Nicola Sturgeon, First Minister of Scotland, said: “Life sciences is an exciting and developing growth sector for Scotland’s economy and it is testament to confidence in the sector that REPROCELL has decided to base its European operations here. The jobs being created and safeguarded will provide significant benefit to the surrounding area and I am looking forward to seeing the company go from strength to strength in the future.”
The company’s relocation to the West of Scotland Science Park was supported by £150,000 of Regional Selective Assistance from Scottish Enterprise in December 2016. Since then, REPROCELL has invested a further £630,000 to expand its European headquarters and develop its product and service offering.
REPROCELL has expertise in the development of predictive assays using stem cells, 3D tissue models and fresh human tissues, offering the pharmaceutical industry novel tools for investigating the safety and efficacy of new drug candidates early in the drug discovery process.
The Centre for Predictive Drug Discovery will allow the company to continue to develop these lines of business, by growing its Glasgow based workforce and expanding operations to focus on the launch of new services.
Dr David Bunton, CEO of REPROCELL Europe, said: “Scottish Enterprise has worked closely with the company in Scotland, Europe, US and Japan to provide business support. This has included work from SDI field colleagues in Japan and across Europe to help identify potential customers, as well as tailored company support on the ground in Scotland to look at new market opportunities globally and extend existing testing services.”
